Ranked #1,232 of 8,699 institutional investors
BVF Inc/il
San Francisco, CA
$2.74B
US stock portfolio at live prices · today −$10.6M (−0.38%)
Market closed. Prices as of Nov 20, 6:41 AM ET
- Value at quarter end (Q3 2026)
- $3.04B
- Change from Q2 2026
- −$870.9M (−22.27%)
- Positions
- 39 · 2 new, 0 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$483M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesKYMR 16.8%RVMD 14.3%XNCR 7.72%MLTX 6.43%STOK 3.54%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| KYMR Kymera Therapeutics, Inc. | 3,872,052 | $462M | 16.8% | Unchanged |
| RVMD Revolution Medicines, Inc. | 2,460,560 | $392M | 14.3% | Reduced −17% |
| XNCR Xencor, Inc. | 6,227,034 | $212M | 7.72% | Reduced −13% |
| MLTX MoonLake Immunotherapeutics | 16,001,284 | $176M | 6.43% | Unchanged |
| STOK Stoke Therapeutics, Inc. | 3,608,968 | $97.2M | 3.54% | Added +42% |
| ZYME Zymeworks Inc. | 3,464,142 | $93.0M | 3.39% | Reduced −5% |
| PVLA Palvella Therapeutics, Inc. | 607,149 | $88.5M | 3.22% | Reduced −10% |
| TYRA Tyra Biosciences, Inc. | 4,215,886 | $83.2M | 3.03% | Added +186% |
| NKTR Nektar Therapeutics | 2,134,007 | $69.4M | 2.53% | Reduced −11% |
| CGEM Cullinan Therapeutics, Inc. | 5,750,683 | $52.2M | 1.90% | Unchanged |
| KURA Kura Oncology, Inc. | 6,690,108 | $49.2M | 1.79% | Reduced −21% |
| GPCR Structure Therapeutics Inc. | 2,691,426 | $46.1M | 1.68% | Reduced −20% |
| MIRM Mirum Pharmaceuticals, Inc. | 407,226 | $38.9M | 1.42% | Reduced −61% |
| GLUE Monte Rosa Therapeutics, Inc. | 4,276,578 | $38.1M | 1.39% | Reduced −4% |
| OLMA Olema Oncology, Inc. | 5,295,893 | $37.9M | 1.38% | Unchanged |
| SGMT Sagimet Biosciences Inc. | 3,500,000 | $33.7M | 1.23% | Added +40% |
| IMCR Immunocore Holdings plc | 1,230,909 | $32.8M | 1.19% | Reduced −5% |
| FDMT 4D Molecular Therapeutics, Inc. | 2,879,289 | $30.9M | 1.12% | Unchanged |
| ANNX Annexon, Inc. | 8,278,164 | $28.2M | 1.03% | Reduced −5% |
| ALEC Alector, Inc. | 10,046,206 | $23.1M | 0.84% | New |
| QTTB Q32 Bio Inc. | 2,350,000 | $19.9M | 0.73% | Unchanged |
| PYXS Pyxis Oncology, Inc. | 11,826,140 | $19.9M | 0.72% | New |
| ABSI Absci Corporation | 2,361,674 | $19.3M | 0.70% | Unchanged |
| IRON Disc Medicine, Inc. | 233,300 | $17.8M | 0.65% | Reduced −80% |
| AVR Anteris Technologies Global Corp. | 3,000,000 | $15.3M | 0.56% | Unchanged |
| IVVD Invivyd, Inc. | 28,165,000 | $12.6M | 0.46% | Unchanged |
| ELDN Eledon Pharmaceuticals, Inc. | 6,293,282 | $12.0M | 0.44% | Unchanged |
| OKUR OnKure Therapeutics, Inc. | 4,045,278 | $11.2M | 0.41% | Added +25% |
| STRO Sutro Biopharma, Inc. | 1,251,788 | $10.9M | 0.40% | Unchanged |
| FHTX Foghorn Therapeutics Inc. | 5,842,000 | $10.4M | 0.38% | Unchanged |
| AVTX Avalo Therapeutics, Inc. | 907,406 | $6.1M | 0.22% | Reduced −56% |
| IMUX Immunic, Inc. | 765,295 | $5.7M | 0.21% | Unchanged |
| XFOR X4 Pharmaceuticals, Inc. | 1,576,624 | $4.7M | 0.17% | Reduced −29% |
| IMA ImageneBio, Inc. | 1,110,002 | $4.4M | 0.16% | Unchanged |
| MOLN Molecular Partners AG | 1,353,968 | $3.6M | 0.13% | Unchanged |
| IVA Inventiva S.A. | 686,040 | $2.4M | <0.1% | Unchanged |
| TCRX TScan Therapeutics, Inc. | 5,564,290 | $794K | <0.1% | Unchanged |
| ENGNW enGene Therapeutics Inc. | 945,402 | $152K | <0.1% | Unchanged |
| TENX Tenax Therapeutics, Inc. | 25,000 | $35K | <0.1% | Reduced −93% |